The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Crenolanib plus salvage chemotherapy in FLT3-mutant R/R AML: results from a randomized trial
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the results of a randomized, placebo-controlled, double-blind trial (NCT03250338; EudraCT 2017-001600-29) evaluating crenolanib in combination with salvage chemotherapy in patients with FLT3-mutant relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr Cluzeau highlights that the study met its primary endpoint, demonstrating a statistically significant improvement in event-free survival (EFS) in the crenolanib arm. Notably, the benefit of crenolimab treatment was most pronounced in patients with NPM1 co-mutated disease. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
